CN104220455B - 抗‑baff‑抗‑il‑17双特异性抗体 - Google Patents

抗‑baff‑抗‑il‑17双特异性抗体 Download PDF

Info

Publication number
CN104220455B
CN104220455B CN201380020761.7A CN201380020761A CN104220455B CN 104220455 B CN104220455 B CN 104220455B CN 201380020761 A CN201380020761 A CN 201380020761A CN 104220455 B CN104220455 B CN 104220455B
Authority
CN
China
Prior art keywords
seq
polypeptide
bispecific antibody
amino acid
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201380020761.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN104220455A (zh
Inventor
B.艾伦
R.J.本肖普
J.卢
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN104220455A publication Critical patent/CN104220455A/zh
Application granted granted Critical
Publication of CN104220455B publication Critical patent/CN104220455B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380020761.7A 2012-04-20 2013-04-16 抗‑baff‑抗‑il‑17双特异性抗体 Active CN104220455B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
US61/636302 2012-04-20
US201361768747P 2013-02-25 2013-02-25
US61/768747 2013-02-25
PCT/US2013/036677 WO2013158577A1 (en) 2012-04-20 2013-04-16 Anti-baff-anti-il-17 bispecific antibodies

Publications (2)

Publication Number Publication Date
CN104220455A CN104220455A (zh) 2014-12-17
CN104220455B true CN104220455B (zh) 2017-04-26

Family

ID=48539373

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380020761.7A Active CN104220455B (zh) 2012-04-20 2013-04-16 抗‑baff‑抗‑il‑17双特异性抗体

Country Status (39)

Country Link
US (2) US9359448B2 (enExample)
EP (2) EP2838920B1 (enExample)
JP (1) JP6216772B2 (enExample)
KR (1) KR101673735B1 (enExample)
CN (1) CN104220455B (enExample)
AP (1) AP2014008002A0 (enExample)
AR (1) AR090626A1 (enExample)
AU (1) AU2013249546B2 (enExample)
BR (1) BR112014025649A2 (enExample)
CA (1) CA2869148C (enExample)
CL (1) CL2014002616A1 (enExample)
CO (1) CO7160039A2 (enExample)
CR (1) CR20140466A (enExample)
CY (1) CY1118824T1 (enExample)
DK (1) DK2838920T3 (enExample)
DO (1) DOP2014000234A (enExample)
EA (1) EA029185B1 (enExample)
EC (1) ECSP14023405A (enExample)
ES (2) ES2621917T3 (enExample)
GT (1) GT201400217A (enExample)
HR (1) HRP20170468T1 (enExample)
HU (1) HUE032153T2 (enExample)
IL (1) IL234965B (enExample)
IN (1) IN2014MN01876A (enExample)
LT (1) LT2838920T (enExample)
ME (1) ME02596B (enExample)
MX (1) MX367460B (enExample)
MY (1) MY173282A (enExample)
NZ (1) NZ630865A (enExample)
PE (1) PE20142147A1 (enExample)
PH (1) PH12014502333B1 (enExample)
PL (1) PL2838920T3 (enExample)
PT (1) PT2838920T (enExample)
RS (1) RS55729B1 (enExample)
SG (1) SG11201406726PA (enExample)
SI (1) SI2838920T1 (enExample)
TW (1) TWI585103B (enExample)
WO (1) WO2013158577A1 (enExample)
ZA (1) ZA201407272B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011254557B2 (en) 2010-05-20 2015-09-03 Ablynx Nv Biological materials related to HER3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
MX356809B (es) 2013-11-19 2018-06-13 Regeneron Pharma Animales no humanos que tienen un gen del factor activador de celulas b.
CA2934965A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
BR112018001255A2 (pt) * 2015-07-23 2018-09-11 Boehringer Ingelheim International Gmbh composto direcionado à il-23a e fator de ativação de células b (baff) e seus usos
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
EP3735272A4 (en) * 2018-01-05 2021-09-22 Biograph 55, Inc. COMPOSITIONS AND METHODS FOR IMMUNO CANCEROTHERAPY
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子
EP4642812A1 (en) * 2022-12-28 2025-11-05 Suzhou Transcenta Therapeutics Co., Ltd. Bispecific binding protein comprising anti-baff antibody and use thereof
US12173081B2 (en) 2023-03-21 2024-12-24 Biograph 55, Inc. CD19/CD38 multispecific antibodies
WO2025108551A1 (en) 2023-11-23 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025109206A1 (en) 2023-11-22 2025-05-30 Mabylon Ag Multispecific anti-allergen antibodies and uses thereof
WO2025222167A1 (en) * 2024-04-19 2025-10-23 Zb17 Llc Methods of treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541224A (zh) * 2001-08-16 2004-10-27 拮抗性抗-hTNFSF13b人抗体
CN101370525A (zh) * 2005-08-19 2009-02-18 艾博特公司 双重可变结构域免疫球蛋白及其用途
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
ES2672221T3 (es) * 2005-12-13 2018-06-13 Eli Lilly And Company Anticuerpos anti IL-17
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1541224A (zh) * 2001-08-16 2004-10-27 拮抗性抗-hTNFSF13b人抗体
CN101370525A (zh) * 2005-08-19 2009-02-18 艾博特公司 双重可变结构域免疫球蛋白及其用途
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists

Also Published As

Publication number Publication date
AU2013249546B2 (en) 2017-10-26
AR090626A1 (es) 2014-11-26
HUE032153T2 (en) 2017-09-28
HRP20170468T1 (hr) 2017-06-02
AU2013249546A1 (en) 2014-09-25
IN2014MN01876A (enExample) 2015-07-03
CY1118824T1 (el) 2018-01-10
DOP2014000234A (es) 2014-11-30
EA201491622A1 (ru) 2015-01-30
PT2838920T (pt) 2017-05-03
CL2014002616A1 (es) 2015-01-30
PE20142147A1 (es) 2014-12-13
JP6216772B2 (ja) 2017-10-18
MX2014012692A (es) 2015-01-22
EP2838920B1 (en) 2017-02-01
PH12014502333A1 (en) 2014-12-22
EP3192809A1 (en) 2017-07-19
ME02596B (me) 2017-06-20
EA029185B1 (ru) 2018-02-28
RS55729B1 (sr) 2017-07-31
US9359448B2 (en) 2016-06-07
CR20140466A (es) 2014-11-13
US20130280256A1 (en) 2013-10-24
GT201400217A (es) 2015-06-02
CO7160039A2 (es) 2015-01-15
TWI585103B (zh) 2017-06-01
KR101673735B1 (ko) 2016-11-07
SG11201406726PA (en) 2014-11-27
AP2014008002A0 (en) 2014-10-31
MX367460B (es) 2019-08-22
ES2621917T3 (es) 2017-07-05
NZ630865A (en) 2016-02-26
PL2838920T3 (pl) 2017-07-31
US9708402B2 (en) 2017-07-18
US20160251430A1 (en) 2016-09-01
IL234965B (en) 2018-04-30
MY173282A (en) 2020-01-10
LT2838920T (lt) 2017-05-25
EP2838920A1 (en) 2015-02-25
CA2869148C (en) 2017-06-20
KR20140135830A (ko) 2014-11-26
TW201402607A (zh) 2014-01-16
ZA201407272B (en) 2016-11-30
CN104220455A (zh) 2014-12-17
WO2013158577A1 (en) 2013-10-24
SI2838920T1 (sl) 2017-03-31
HK1201862A1 (en) 2015-09-11
BR112014025649A2 (pt) 2017-07-04
EP3192809B1 (en) 2020-04-15
CA2869148A1 (en) 2013-10-24
PH12014502333B1 (en) 2014-12-22
ECSP14023405A (es) 2015-09-30
JP2015514423A (ja) 2015-05-21
ES2789474T3 (es) 2020-10-26
DK2838920T3 (en) 2017-04-18

Similar Documents

Publication Publication Date Title
CN104220455B (zh) 抗‑baff‑抗‑il‑17双特异性抗体
KR102266144B1 (ko) 항-il-33 항체 및 그의 용도
CA2501653C (en) Human anti-ifn-.gamma. neutralizing antibodies as selective ifn-.gamma. pathway inhibitors
KR20090088950A (ko) 가공된 항-ｔｓｌｐ 항체
KR102294051B1 (ko) Btla 효능제 항체 및 이의 용도
KR102453573B1 (ko) 항-pacap 항체
KR101712874B1 (ko) 인간화 항 TNF α 항체 및 그의 항원 결합 단편 (Fab) 및 용도
CN101918549B (zh) 改良的人源化的抗-人α9-整联蛋白抗体
HK1201862B (en) Anti-baff-anti-il-17 bispecific antibodies

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant